🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Priya Life Science Sponsor trial record
Trackers Companies Trial finder
Sponsor · clinical trials

Chengdu Zenitar Biomedical Technology clinical trials

Source: ClinicalTrials.gov, U.S. National Library of Medicine — current trials in our China register with Chengdu Zenitar Biomedical Technology as lead sponsor. Synced 26 Sep 2026
14Current trials
8Recruiting now
5Drugs in these trials
1Trial register
Maintained by Sreepriya Prasannan
MSc Digital Transformation of Life Sciences (Innopharma Education / Griffith College); MSc & BSc Botany HSE Spark Ignite 2026 — Top 14 finalist
Compiled from ClinicalTrials.gov and CTIS registry records · Last verified · Editorial standards
At a glance

Chengdu Zenitar Biomedical Technology is the lead sponsor of 14 current clinical trials in our China register. 8 are recruiting patients now. The most common phase is Phase 2. The drugs named most often in its trials are Flonoltinib, Purinostat Mesylate and Ruxolitinib. The most-studied condition is MF.

ClinicalTrials.gov trials by status

  • Recruiting857%
  • Not yet open321%
  • Active, closed321%

Trials by phase

  • Phase 2643%
  • Phase 1321%
  • Phase 1/2321%
  • Phase 3214%
01

Clinical trials sponsored by Chengdu Zenitar Biomedical Technology

14 on ClinicalTrials.gov
StudyPhaseStatusStartRegisters
A Clinical Trial of Flonoltinib Maleate for Intermediate or High-Risk Myelofibrosis
NCT07317700 · ClinicalTrials.gov ↗ · MF
Phase 3 Recruiting 2026-02 China
A Phase II Clinical Study Evaluating of ZL-82 Tablets in Atopic Dermatitis
NCT07193589 · ClinicalTrials.gov ↗ · Atopic Dermatitis
Phase 2 Recruiting 2026-02 China
Purinostat Mesylate Combined With Pomalidomide Capsules and Low-dose Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma
NCT06484829 · ClinicalTrials.gov ↗ · Relapsed or Refractory Multiple Myeloma (RRMM)
Phase 1/2 Recruiting 2024-03 China
A Clinical Study of Purinostat Mesylate for Injection in Patients With Advanced Solid Tumors
NCT06431243 · ClinicalTrials.gov ↗ · Advanced Solid Tumor
Phase 1/2 Recruiting 2024-05 China
A Clinical Trial of Flonoltinib Maleate Tablets in the Treatment of JAK Inhibitor Refractory/Relapsed/Intolerant Patients With Intermediate to High Risk Myelofibrosis
NCT07443306 · ClinicalTrials.gov ↗ · MF
Phase 2 Recruiting 2026-03 China
Phase IIa Study of Flonoltinib Maleate Tablets in the Treatment of Patients With Polycythemia Vera
NCT07232290 · ClinicalTrials.gov ↗ · Polycythemia Vera (PV)
Phase 2 Recruiting 2025-09 China
A Phase III Clinical Study of Purinostat Mesylate for Injection in Patients With Diffuse Large B-cell Lymphoma
NCT07011056 · ClinicalTrials.gov ↗ · Recurrent and Refractory Diffuse Large B-cell Lymphoma
Phase 3 Recruiting 2025-07 China
Phase I Clinical Study of ZL-65 Tablet in Healthy Adult Participants in China
NCT07757152 · ClinicalTrials.gov ↗ · Healthy Participants Study
Phase 1 Recruiting 2026-07 China
Clinical Study on Drug Interactions of Flonoltinib Maleate Tablets
NCT07768111 · ClinicalTrials.gov ↗ · Drug Interaction Research
Phase 1 Not yet open 2026-10 China
A Clinical Study of ZL-85FA Tablets
NCT07339748 · ClinicalTrials.gov ↗ · Advanced Solid Tumor
Phase 1/2 Not yet open 2026-06 China
Mass Balance Study of [¹⁴C]Purinostat Mesylate for Injection in Healthy Participants
NCT07809217 · ClinicalTrials.gov ↗ · MB
Phase 1 Not yet open 2026-09 China
Study of Purinostat Mesylate for Injection in the Treatment of Relapsed or Refractory Diffuse Large B-cell Lymphoma (R/R DLBCL)
NCT05563844 · ClinicalTrials.gov ↗ · Diffuse Large B Cell Lymphoma,DLBCL
Phase 2 Active, closed 2022-11 China
A Phase IIa Clinical Study of Purinostat Mesylate for Injection in Patients With Peripheral T-Cell Lymphoma and Cutaneous T-Cell Lymphoma
NCT06485219 · ClinicalTrials.gov ↗ · Relapsed or Refractory Peripheral T-cell Lymphoma (PTCL), Cutaneous T-cell Lymphoma (CTCL)
Phase 2 Active, closed 2024-04 China
A Phase II Clinical Trial of Flonoltinib Maleate Tablet in Intermediate-High Risk Myelofibrosis
NCT06457425 · ClinicalTrials.gov ↗ · MF,PMF,PPV-MF,PET-MF
Phase 2 Active, closed 2024-05 China

Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Titles and statuses are copied from the registry as published.

02

Drugs in Chengdu Zenitar Biomedical Technology trials

5 compounds

Drugs and biologicals named as interventions in these trials, with the number of this sponsor's trials that name each one. Placebos and generic comparators are excluded.

03

Conditions in Chengdu Zenitar Biomedical Technology trials

13 conditions
MF2Advanced Solid Tumor2Atopic Dermatitis1Drug Interaction Research1Relapsed or Refractory Multiple Myeloma (RRMM)1Diffuse Large B Cell Lymphoma,DLBCL1Polycythemia Vera (PV)1Recurrent and Refractory Diffuse Large B-cell Lymphoma1MB1Healthy Participants Study1Relapsed or Refractory Peripheral T-cell Lymphoma (PTCL)1Cutaneous T-cell Lymphoma (CTCL)1MF,PMF,PPV-MF,PET-MF1
04

By trial register

RegisterTrialsRecruiting
Clinical trials in China148

A trial with sites in more than one country appears in each of those registers.

05

Questions about Chengdu Zenitar Biomedical Technology trials

How many clinical trials does Chengdu Zenitar Biomedical Technology sponsor?

Chengdu Zenitar Biomedical Technology is the lead sponsor of 14 current trials on ClinicalTrials.gov in our China register, as of the registry sync on 26 September 2026. Completed and withdrawn studies are not counted.

Are Chengdu Zenitar Biomedical Technology trials recruiting?

Yes. 8 of its 14 ClinicalTrials.gov trials are recruiting. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.

Which drugs is Chengdu Zenitar Biomedical Technology testing?

Its current trials name 5 drugs and biologicals as interventions. The most frequent are Flonoltinib (4), Purinostat Mesylate (3), Ruxolitinib (1), Ruxolitinib Phosphate (1) and Selinexor (1). The number in brackets is how many of its trials name each drug.

Where does this information come from?

Every trial, status, phase and condition on this page is copied from public ClinicalTrials.gov and EU CTIS records by a daily sync, grouped by the sponsor name each registry records. It says nothing about the organisation beyond its registered trials, and it is not medical advice.

Approvals, shortages and trials, every Friday

One email a week with new EMA and FDA approvals, EU and US medicine shortages, how many trials are recruiting in Ireland, and the week's Irish pharma news.

Free. Unsubscribe from any email with one click. See our privacy policy.

How this page is built

Everything on this page is copied from public registry records — it is not written from memory, and nothing here describes the organisation beyond its registered trials. Each trial links to its own record so you can check it yourself.

This page is built automatically: a daily sync job reads the registry records behind our trial registers and groups every current trial by its lead sponsor name, ignoring legal-form suffixes such as Inc. or Ltd. A small, hand-checked list joins the same organisation's different registry names (for example its EU legal entity). There is no AI drafting and no per-sponsor editorial pass. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The the registries data on this page was last retrieved on 26 Sep 2026.

Please verify before you rely on this. This page is general information for life-science and pharmaceutical professionals. It is not medical advice, and it has not been reviewed by a clinician — our editorial team holds life-science qualifications, not clinical ones. It is not exhaustive and may not reflect the most recent label change. Always check the official prescribing information (US Prescribing Information or EU SmPC) and speak to your doctor or pharmacist before acting on anything here. Drugs in the same class are not automatically interchangeable, and approvals, brand names and indications differ between the US, the EU/Ireland (EMA/HPRA) and other regions. Spotted an error? Tell us — we correct promptly and log it.